Breaking News
July 21, 2018 - Species diversity can have positive and negative impacts on disease transmission
July 21, 2018 - Genome research suggests presence of enteric fever in medieval Europe
July 21, 2018 - Risk of Sensory Deficits Drops With Rising Gestational Age
July 21, 2018 - Mum’s sleep matters—the effect of sleep on an unborn baby
July 21, 2018 - UC San Diego researchers awarded two grants for investigating stem cell-based therapies
July 21, 2018 - Cellular ‘garbage disposal’ may actually work on some of the proteins to neuronal development
July 21, 2018 - More Pregnant Women Having Heart Attacks
July 21, 2018 - Acne Breakouts | NIH News in Health
July 21, 2018 - Change health messaging to focus on potential impact to help stop the next pandemic
July 21, 2018 - Frailty associated with poor survival rates in young heart patients
July 21, 2018 - New discovery could save millions of lives from fatal fungal infections
July 21, 2018 - OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes
July 21, 2018 - Childhood adversity increases susceptibility to addiction via immune response
July 21, 2018 - Scientists identify potential target for the treatment of binge eating
July 21, 2018 - Whole-brain LIPUS therapy improves cognitive dysfunction in mice simulating dementia, Alzheimer’s
July 21, 2018 - Digital media use raising risk of ADHD symptoms among the young
July 21, 2018 - Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints
July 21, 2018 - Restoring mitochondrial function to reverse aging-related skin wrinkles, hair loss in mice
July 21, 2018 - SP PennTech introduces RW-500 rotary vial washer for biotech, pharmaceutical applications
July 21, 2018 - Researchers to study molecular mechanisms behind susceptibility of males to autism
July 21, 2018 - Fourth Published Clinical Trial Confirms Long-Term Safety of Niagen Supplementation at High Doses and Shows Potential for Improvement in Liver Health
July 21, 2018 - Greening vacant urban land reduces feelings of depression for surrounding residents
July 21, 2018 - Parents say intense gun violence in PG-13 movies appropriate for teens 15 and older
July 21, 2018 - Collaborative study to assess effects of exercise training for cognitive deficits in MS
July 21, 2018 - FAU researchers find possible cause of Parkinson’s disease in the patients’ immune system
July 21, 2018 - Protective qualities of ‘good cholesterol’ reduce after menopause
July 21, 2018 - Researchers develop new way to uncover hidden breast cancer tumors
July 21, 2018 - FDA approves first drug for treatment of adult AML patients with specific genetic mutation
July 21, 2018 - Top AI companies join hands to discover novel drugs for DMD
July 21, 2018 - Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications
July 20, 2018 - Researchers design proteins that can self-assemble into complex structures
July 20, 2018 - AVITA Medical expands management team to support launch of RECELL device to treat burns
July 20, 2018 - FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation
July 20, 2018 - Developmental screening and surveillance rates remain low, new study suggests
July 20, 2018 - TGen opens tissue donation portal to advance DIPG research
July 20, 2018 - Health impact of highly processed summertime staples
July 20, 2018 - Exergaming can improve health in overweight and obese children, study shows
July 20, 2018 - Postmenopausal factors may impact heart-protective qualities of ‘good cholesterol’
July 20, 2018 - MRI and blood test combination results in improved prostate cancer diagnosis
July 20, 2018 - Update Health Professional and Consumer on Recent Recalled Products
July 20, 2018 - Researchers trace Parkinson’s damage in the heart
July 20, 2018 - Wearable device designed to measure cortisol in sweat
July 20, 2018 - Scientists demonstrate a new regulation mechanism for skeletal muscles
July 20, 2018 - Exposure to mobile phone radiation may negatively impact memory performance in adolescents
July 20, 2018 - SUSU scientists find alternative method to treat post-traumatic stress disorder syndrome
July 20, 2018 - Gestational diabetes may increase offspring’s heart disease risk
July 20, 2018 - New vaccine could protect unborn babies from Zika virus
July 20, 2018 - Researchers find high mercury and methylmercury concentrations in traditional Tibetan medicine
July 20, 2018 - Brief Safety Plan Intervention in ER Can Cut Suicidal Behavior
July 20, 2018 - The Mount Sinai Hospital receives accreditation as geriatric emergency department
July 20, 2018 - Toward a better understanding of Parkinson’s disease
July 20, 2018 - Med school communications office wins four national awards | News Center
July 20, 2018 - Professional baseball players with faster hand-eye coordination may have better batting performance
July 20, 2018 - Study looks into mechanisms that control sleep and wakefulness
July 20, 2018 - Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments
July 20, 2018 - Research reveals long-term efficacy of drug used to treat common cause of kidney failure
July 20, 2018 - Timing of dinner associated with breast and prostate cancer risks
July 20, 2018 - Health Tip: Performing the Heimlich Maneuver
July 20, 2018 - Nearly all adolescents have eating, activity or weight-related issues
July 20, 2018 - Sage launches new web-based tool that helps explore curated genomic analyses of Alzheimer’s
July 20, 2018 - High-performance porous polymeric material for chromatography applications
July 20, 2018 - New molecule shows great promise for future treatment of many cancers
July 20, 2018 - New research project investigates alternative treatments for eye infections
July 20, 2018 - Immune T cells are built to react as fast as possible, shows study
July 20, 2018 - ZHX2 protein could offer a new treatment strategy for kidney cancer
July 20, 2018 - EKF’s Quo-Lab POC HbA1c analyzer meets international quality targets for diabetes testing
July 20, 2018 - Health burdens of very high risk drinking are potentially large, study reveals
July 20, 2018 - Using miniature drug-filled nanocarriers to target headaches and tumors
July 20, 2018 - Researchers uncover cause for progression of prostate cancer to incurable stage
July 20, 2018 - Studies highlight issues regarding black lung, opioid overdose, police violence and more
July 20, 2018 - AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia
July 20, 2018 - Researchers are one step closer to developing eye drops to treat age-related macular degeneration (AMD)
July 20, 2018 - Patients maintain muscle mass five years after surgically induced weight loss
July 20, 2018 - AMSBIO introduces new, powerful CRISPR/Cas9 gene editing kits
July 20, 2018 - PureTech Health collaborates with Roche to advance oral administration of antisense oligonucleotides
July 20, 2018 - Analysis reveals disparities in cancer death rates among minority groups
July 20, 2018 - Dr Maddy Parsons receives Royal Microscopical Society Life Science Medal
July 20, 2018 - Study finds link between DNA methylation and non-alcoholic fatty liver disease
July 20, 2018 - Military personnel with head trauma and football players with suspected CTE show similar brain changes
July 20, 2018 - Vidac Pharma Announces Initiation of Phase 2b Clinical Trial of VDA-1102 Ointment in Patients with Actinic Keratosis
Autoinjected Secukinumab a Hit in Psoriatic Arthritis

Autoinjected Secukinumab a Hit in Psoriatic Arthritis

image_pdfDownload PDFimage_print

Action Points

  • Note that this randomized study found that the Il-17a inhibitor secukinumab was efficacious in improving symptoms among patients with psoriatic arthritis.
  • Be aware that the medication fared best among those who had not previously been treated with an anti-TNF agent. Higher doses may be needed for those who were previously exposed.

The interleukin (IL)-17A inhibitor secukinumab (Cosentyx) provided durable benefits in the treatment of psoriatic arthritis, and patient satisfaction with self-administration using an autoinjector was high, researchers found.

At week 24 in a phase III trial known as FUTURE 3, improvements of at least 20% on the criteria of the American College of Rheumatology (ACR20) were seen in 48.2% of patients receiving 300 mg of secukinumab every 4 weeks and in 42% of those receiving 150 mg, compared with 16.1% of those given placebo (P<0.0001), according to Peter Nash, MD, of the University of Queensland in Brisbane, Australia, and colleagues.

Week 24 was the end of the placebo-controlled phase of the study. By week 52, when all patients were receiving the active treatment, ACR20 response rates rose to 58.3% and 47.1% in the 300- and 150-mg groups, respectively.

And at least 88% of patients said that they were satisfied or very satisfied with the autoinjector, finding it easy or very easy to use, the researchers reported in Arthritis Research & Therapy.

The efficacy findings confirm what has previously been seen in other phase III trials of subcutaneous secukinumab. For example, in a study known as FUTURE 1, published in 2015 in the New England Journal of Medicine, ACR20 responses at week 24 were observed in 50% of patients receiving 150 mg monthly and in 50.5% of those receiving 75 mg. In FUTURE 2, published the same year in The Lancet, 54% of patients receiving 300 mg had ACR20 responses at week 24, as did 51% of those given 150 mg.

FUTURE 3 is an ongoing randomized trial being conducted at 74 centers worldwide. Participants have active disease, defined as at least three tender and swollen joints, and could have previously received up to three tumor necrosis factor (TNF) inhibitors.

A total of 414 patients were enrolled. Mean age was 50, slightly more than half were women, and more than 90% were white. Mean time since the diagnosis of psoriatic arthritis ranged from 6.6 to 8.3 years, and one-third had previously received a TNF inhibitor. Mean number of tender and swollen joints were 21 and 10, respectively.

Almost half were using methotrexate at baseline.

In general, patients who were anti-TNF naive fared better. At week 24, the ACR20 and ACR50 responses among patients who were anti-TNF naive were 51.6% and 45.7% in the 300 mg and 150 mg groups, respectively, while in patients who had previously had an inadequate response to anti-TNF treatment, the response rates in the two dosage groups were 40.9% and 34.1%.

The greater responses seen with the higher dose among patients with previous anti-TNF exposure suggests that the 300 mg dose is appropriate for these refractory patients, the authors indicated.

On the Psoriasis Area and Severity Index (PASI), improvements of 75% were seen in 61.3% and 55.9% of the 300- and 150-mg groups at week 24, compared with 11.9% of the placebo group. At week 52, PASI75 responses were seen in 74.2% of the 300-mg group and in 60.3% of the 150-mg group.

On the Health Assessment Questionnaire-Disability Index (HAQ-DI) changes from baseline at week 24 were -0.38 in the 300-mg group and -0.27 in the 150-mg group compared with -0.17 in the placebo group, and mean changes in pain scores were -18.23 and-12.46 versus -3.75. At week 52, changes from baseline on the HAQ-DI were -0.43 and -0.30 in the 300 mg and 150 mg groups, while changes in pain scores were -20.3 and -11.8.

During the 52 weeks, the incidence rates of adverse events were 194.9 and 192.5 per 100 patient-years, while the rates of serious adverse events were 8.8 and 10.2 per 100. Two deaths occurred — one pancreatic cancer and one small cell lung cancer.

Candida infections were an adverse event of special interest, because IL-17 plays a crucial role in mucocutaneous defense against fungal and bacterial infections. Oral candidiasis was reported in three patients in the 300-mg group and five patients in the 150-mg group, and two patients in each dose group experienced vulvovaginal candidiasis. Patients on secukinumab should be observed closely for Candida infections, the researchers noted.

Neutropenia developed in two patients in the 150-mg group and one patient in the 300-mg group.

“In summary, self-administration of subcutaneous secukinumab provided sustained improvements at 52 weeks across multiple clinical domains in patients with active psoriatic arthritis,” Nash and colleagues concluded, adding that patients were satisfied with the autoinjector device.

A limitation of the study was the lack of a placebo control after week 24.

The study was funded by Novartis Pharma.

The authors reported financial relationships with Novartis, AbbVie, Roche, Pfizer, Bristol-Myers Squibb, Janssen, Celgene, Crescendo Bioscience, Genentech, Eli Lilly, Merck, UCB, and Amgen. Several are employees of Novartis.

2018-03-16T15:30:00-0400

Tagged with:

About author

Related Articles